Maspin has been demonstrated to be a suppressor of invasion and cell motility in vitro, whereas in vivo analyses have reported that increased expression of maspin is associated with malignant behavior. The present study examined maspin expression in normal lung and nonsmall-cell lung cancers. Only proximal airway cells in the normal lung expressed maspin, and the expression was associated with decreased methylation. This association was also observed in non-small-cell lung cancers, but the expression was quite different among histologic subtypes; 20 of 21 squamous cell carcinomas showed intense, uniform expression, whereas the expression status varied among adenocarcinomas. Of the 119 adenocarcinomas, 60 were negative, 23 positive and 36 showed a heterogeneous expression pattern. The expression was inversely correlated with markers of peripheral airway cells. Taken together, the results suggest that maspin may be expressed in association with the proximal airway cell type. It is of note that the heterogeneous expression pattern of maspin is quite distinctive, showing geographic positivity in the individual tumors. Separate analysis of methylation status in positive and negative portions of individual tumors provided an instance of intratumor diversity associated with promoter DNA methylation.
Introduction
The mammary serine protease inhibitor maspin was first isolated by Zou et al. (1994) as a defective molecule in breast carcinoma cells by differential display analysis. Maspin exhibits significant homology to the serpin superfamily of serine protease inhibitors, which includes the plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), and a1-antitrypsin. Recent analyses in vitro have suggested an inhibitory effect on tumor invasion and metastasis. Cell motility and invasion are inhibited with transfection of the maspin gene into cancer cell lines, and the transplantation of the transfectants in nude mice led to reduced tumorgenicity and decreased metastatic potential Zou et al., 1994; Sheng et al., 1996; Zou et al., 2000) . The mechanism underlying maspin's inhibitory activity remains controversial, but recent reports suggested that it does not directly inhibit matrix-degrading proteases, but rather functions as a regulator of plasminogen-tissue-type plasminogen activator complex (Bass et al., 2002) . On the other hand, it has been shown that maspin has two consensus p53-binding sequences in its promoter region, and p53 regulated maspin expression, indicating that maspin is one of the target genes of p53 pathway (Zou et al., 2000) . Furthermore, maspin was shown to have an inhibitory effect on tumor angiogenesis (Zhang et al., 2000) and a sensitizing effect on apoptosis (Jiang et al., 2002) . Despite a tumor suppressing role in vitro, clinicopathological analysis using in vivo tumors failed to demonstrate the role, and maspin-expressing tumors tend to show more malignant behavior, including shorter survivals, in breast cancers (Umekita et al., 2002; Bieche et al., 2003) , pancreatic cancers (Maass et al., 2001 ) and ovarian cancers (Sood et al., 2002) .
Promoter DNA hypermethylation is one of the epigenetic mechanisms to silence certain genes. So far, a number of genes have been shown to be inactivated by this gene silencing (Jones and Baylin, 2002; Laird, 2003) , whereas the silencing was predominantly reported in the cancer tissues, but not in normal tissues. Although the involvement of DNA methylation in X-chromosome inactivation (Mohandas et al., 1981) and genomic imprinting (Li et al., 1993) has been widely accepted, tissue-specific regulation of gene expression in normal tissues mediated by DNA methylation has long been speculated. Recently, Futscher et al. (2002) first demonstrated that the tissue-specific expression of maspin was controlled by DNA methylation. They described a close correlation between maspin expression and the absence of DNA methylation using various normal tissues, and this expression in immortalized cells was restored by treatment with 5-aza-2 0 -deoxycytidine. In addition to normal tissues, the gene silencing of maspin was observed in breast cancers (Domann et al., 2000; Maass et al., 2002) , suggesting a contribution to breast carcinogenesis.
Lung cancers, especially adenocarcinomas, are characterized by a high degree of morphological heterogeneity, which in turn implies both intra-and intertumor diversities. We have been interested in and have analysed the diversities. Recently, we revealed that thyroid transcription factor-1, TTF-1, serves as a lineage marker for peripheral airway cells, including type I and II pneumocytes (Yatabe et al., 2002) . Furthermore, analysis of various cancer-associated genes, including p53 (Nishio et al., 1997) , cyclin D1 (Nishio et al., 1997) , RB (Nishio et al., 1997), p27 Kip1 (Yatabe et al., 1998b ) and COX1 (Yatabe et al., 1998a; Achiwa et al., 1999) , suggests a different molecular pathway for carcinogenesis in lung adenocarcinomas between cells with and without TTF-1 expression. This result implies that one of the intertumor heterogeneities of lung adenocarcinoma is represented by putative original cells, that is, peripheral airway cell-derived carcinomas and the others. This distinction is supported by the expression profiling analysis (Bhattacharjee et al., 2001; Garber et al., 2001) . Unsupervised hierarchical clustering, based on the molecular signature, classified lung adenocarcinomas largely into two subtypes, which were delineated by TTF-1. The present study also focused on the diversities. First, we confirmed cell-type-specific expression of maspin, and then we examined lung tumors, revealing that maspin is expressed in a highly heterogeneous fashion in lung adenocarcinomas, similar to the morphology. We found that the expression of maspin is associated with cell type in lung tissue, while intratumor diversity of maspin is associated with regional promoter hypermethylation. There are few references in the literature concerning DNA methylation associated with the intratumor diversity Nass et al., 2000; Markl et al., 2001) , and this study therefore provides new information regarding maspin expression, which might shed light on the complex mechanism of the metastatic process.
Results
Cell-type-specific expression of maspin in the normal lung Tissue-specific expression, including airway epithelium, has been previously reported (Futscher et al., 2002) , but there are various types of the epithelium covering airway tracts. Therefore, we further examined which cell types in the airway epithelium expressed maspin. Immunohistochemical analysis demonstrated a characteristic expression pattern, and this expression was restricted to the basal cells of the bronchial epithelium (Figure 1 (a1) ) and myoepithelium of the bronchial glandular acini (Figure 1 (a2) ). This was in sharp contrast to the peripheral portion of the lung parenchyma; none of the cells in the peripheral lung, such as type I and II pneumocytes, were positive for maspin (Figure 1 (a4) ). In the bronchiolar cells that connect the bronchus to the peripheral lung, a number of maspin-expressing cells were decreased (Figure 1 (a3) ).
Maspin expression in lung cancers
Similar to the normal lung, a cell-type-specific pattern of maspin expression was observed in non-small-cell lung cancers ( Table 1 ). All of the squamous cell carcinomas, except a single case, expressed maspin intensively and very uniformly (Figure 1b ), whereas adenocarcinomas demonstrated a variety of expression patterns (Figure 1c and d). Of the 119 adenocarcinomas, 60 (50.4%) were negative for maspin, while 23 (19.3%) demonstrated a uniform, and 36 (30.3%) a heterogeneous expression pattern for maspin. The heterogeneous expression pattern of maspin was quite distinctive, and details are discussed later.
Columnar cell-specific expression in normal lung tissue prompted us to explore the biological significance of maspin expression in pulmonary adenocarcinomas. First, we examined the clinicopathological characteristics of the maspin-positive adenocarcinoma, which is summarized in Table 2 . Although maspin expression was not associated with sex, smoking status or Figure 1 Maspin expression in normal lung tissue (a) from a proximal airway (a1) to peripheral lung parenchyma (a4). Basal cells of the bronchial surface epithelium (a1), and myoepithelium of the bronchial glands (a2), expressed maspin. Positive signal frequency was reduced as being close to the alveolar spaces (bronchioles, A3), and no expression was detected in the alveolar spaces (a4). Squamous cell carcinoma (b) demonstrates intense, uniform expression, whereas the expression was varied among adenocarcinomas. A similar positive pattern was seen in mucinous bronchioloalveolar carcinoma (c). However, an ordinary peripheral type of adenocarcinoma is completely negative for maspin despite the positive internal control for bronchial epithelium (d) pathological stage, maspin expression was more frequently observed in advanced local tumor status (pT). In the scheme of lung cancer staging classification, pT is determined by tumor size and an extent of local invasion. Individual analysis of tumor size and local invasiveness revealed that the correlation of maspin expression with pT was primarily dependent on the prevalence of maspin expression in larger tumors, but not that of locally invasive tumors. In addition, the presence of lymph node metastasis was independent of maspin expression.
We have recently proposed the subclassification of lung adenocarcinoma into two major subtypes of peripheral airway adenocarcinoma and the remainder, which are delimited by TTF-1. Interestingly, maspin expression is inversely correlated with TTF-1 expression, being consistent with proximal airway-specific expression of maspin in the normal lung. This was confirmed by the expression status of surfactant precursor protein B, which is known as a differentiation marker for pneumocytes. p53 alteration is frequent in maspin-expressing adenocarcinomas, and is also consistent with less-frequent p53 alteration in TTF-1-positive adenocarcinomas. Therefore, this suggests that maspin is expressed in association with cellular type of the nonperipheral airway epithelium even after malignant transformation. Selective expression of maspin in normal proximal airway cells suggests that maspin may be expressed in association with proximal airway cell type. The K-ras mutation is also prevalent in maspinexpressing adenocarcinomas.
Heterogeneous expression of maspin in lung cancers
During the examination, we found that the heterogeneous pattern of maspin expression was distinct from the common expression pattern; the expression pattern was very geographic, that is, a part of the tumor intensely expressed maspin, but the other was completely negative (Figure 2 ). In 36 of the 119 adenocarcinoma cases examined, maspin expression varied among the tissue-microarrayed cores in individual tumors. Therefore, we further analysed with regular whole sections, and confirmed the geographic expression of maspin in 36 adenocarcinoma cases. This heterogeneous expression appears to be inconsistent with the idea of proximal airway-cell-type-associated expression of maspin, because characteristic uniform expression of TTF-1 was observed in 25 of 36 adenocarcinomas with heterogeneous maspin expression (Table 2) . On this matter, following two points were addressed. First, we examined the expression status of maspin in preneoplastic lesions and in situ carcinoma of a peripheral type of adenocarcinoma. All five atypical adenomatous hyperplasia and five nonmucinous bronchioloalveolar carcinomas (carcinoma in situ) were positive for TTF-1, but negative for maspin. Second, clinicopathological characteristics of the heterogeneous expression among the TTF-1-positive, peripheral airway cell-associated adenocarcinomas were examined. Heterogeneous expression was associated with higher histologic grade (w 2 test, P ¼ 0.02) and lower frequency of surfactant expression (Fisher's exact test, P ¼ 0.03), suggesting that maspin heterogeneity was prevalent in less-differentiated tumors in the category of peripheral airway cell-associated adenocarcinomas. These findings imply that maspin should be considered as a differentiation marker rather than a lineage marker.
Characteristics of maspin-positive portions in the individual tumors were then analysed. Although there was some unexpected expression, two morphologically characteristic portions tended to be positive for maspin: a portion showing solid growth pattern (Figure 2b) , and a portion with infiltrating cancer cells in small clusters (Figure 2d ). Some adenocarcinomas contained either solid or infiltrating patterns, while the other Figure 3 ). The portions with and without the expression were morphologically indistinguishable. The findings raised a question about which portion was associated with metastasis. We therefore compared the expression pattern between primary and metastatic sites in order to ascertain the role of maspin in metastasis. Of the 36 adenocarcinomas with heterogeneous expression, 13 tumors metastasized to the lymph nodes, with only 12 able to be examined. The results are summarized in Figure 3 , and the expression status in half of the 12 tumors was decreased compared to that of the corresponding lymph nodes.
Maspin expression associated with promoter DNA methylation
The relationship between the expression and methylation status was examined in lung cancer cell lines. The promoter region of the maspin gene was densely methylated in five of 13 cell lines (Table 3 and Figure 4 ). All of the five cell lines showing dense promoter methylation were shown to be negative for maspin expression using real-time PCR. Conversely, all of the cell lines without detectable transcripts demonstrated promoter methylation, except for two cell lines, ACC-LC-172 (SCLC) and VMRC-LCD (adenocarcinoma).
In the normal tissues, no expression was observed in the peripheral lung and, consistently, the promoter region of the maspin gene in the tissues was densely methylated. Methylation of the six peripheral lung tissues reached 89.6% on average. Similarly, 91.5% of CpG sites examined were methylated in lymph nodes, where no maspin expression was detected. In contrast, percentage methylation of microdissected bronchial Figure 4 Relationship between promoter DNA methylation and expression status in normal lung tissue, lung cancer cell lines and non-small-cell carcinoma in vivo (a). Lines in the chart between positive and negative expression indicate the shift in methylation patterns between positive and negative portions in individual cases with heterogeneous expression, which were examined separately. A representative frozen section examined is shown (b). Positive and negative portions were separately microdissected and examined. Representative results are listed in (c) Maspin expression in lung cancers Y Yatabe et al epithelium from two individuals was 32.3 and 43.1%. Bronchial epithelium was only a part of the lung tissue that expressed maspin, but the expression was limited to the basal layer. The whole layer of bronchial epithelium was able to be microdissected, and thus, the results represented the methylation status of mixed bronchial epithelium with and without maspin expression. These results indicated that methylation and expression are well correlated, suggesting cell-type-associated promoter DNA methylation.
We then examined the correlation of expression and methylation status in tumors in vivo (Table 3) . As in normal tissue, six of the squamous cell carcinoma and six adenocarcinomas with uniform maspin expression had almost no methylated CpG sites in the promoter region of maspin gene (2.0 and 8.2% on average, respectively). Methylation patterns in seven adenocarcinomas without maspin expression were contrasted, and the promoter region was methylated in six of the seven tumors. In three adenocarcinomas with heterogeneous expression, portions with and without maspin expression were separately microdissected, and the methylation status was independently accessed. The portions without detectable maspin expression contained a more intensely methylated promoter than that with maspin expression (Figure 4) . The results suggested that the expression of maspin was correlated with methylation status both between and within tumors.
Discussion
The current study demonstrated that maspin is not expressed in the lung parenchyma, but specifically in bronchial epithelium, of which basal cells were the predominant source of expression. As promoter DNA methylation in the bronchial epithelium was contrasted to that in lung parenchyma, this suggests that the expression is associated with promoter DNA methylation. This observation extends the finding of Futscher et al. (2002) that promoter hypermethylation plays a role in the maintenance of cell-specific expression. Differences in whole genomic methylation patterns among various tissues with restriction landmark genomic scanning (Kawai et al., 1993) also supports the hypothesis.
It has been widely accepted that promoter DNA hypermethylation is one of the mechanisms that inactivate tumor suppressor gene. Although maspin is frequently documented to function as a tumor suppressor in vitro, current work suggests that the expression status of maspin in non-small-cell lung cancers is reflected in its expression in corresponding normal lung tissues. Selective expression of maspin in normal proximal airway cells suggests that maspin may be expressed in association with proximal airway cell type. Indeed, uniform expression of maspin in squamous cell carcinoma is consistent with the idea that squamous cell carcinoma is likely to be derived from proximal airway cells through the metaplasia-dysplasia-carcinoma sequence. We have recently reported that TTF-1 is useful for the distinction of peripheral airway cellderived adenocarcinomas (Yatabe et al., 2002) . The expression status of TTF-1 is inversely correlated with that of maspin in adenocarcinomas, suggesting that maspin expression is not associated with the role of tumor suppressor, but that simply is a reflection of the cell type of the proximal airway cells. This may explain the discrepancies between several reports examining tumors in vivo and suggesting a role in vitro. For example, in breast cancers, two articles have reported that maspin expression is associated with a higher histological grade, lack of estrogen receptor expression and poor prognosis (Umekita et al., 2002; Bieche et al., 2003) . Nevertheless, breast cancer cell lines, which were transfected with the maspin gene, suppressed motility and invasion in vitro (Zou et al., 1994; Sheng et al., 1996) . Linkage of the discrepant findings may be present in the fact that maspin expression is restricted to the basal/myoepithelium of the ducts in the normal breast. According to the molecular profiles, cDNA microarray analysis subdivides breast cancers into three subtypes, which include luminal, basal and ERBB2 þ types (Perou et al., 2000; Sorlie et al., 2003) . One of the subtypes, the basal cell type, is characterized by (1) high expression of the basal cell markers, cytokeratin 5 and 17; (2) negative expression of estrogen receptor and progesterone; and (3) clinical aggressiveness. Although the expression status of maspin is not available in the classification, the characteristics of this basal cell type resembles those of maspin-expressing tumors, suggesting that maspin expression in breast cancers may also be simply reflected in certain cellular properties rather than tumor-suppressive function of maspin. This hypothesis does not deny the finding observed in vitro and, indeed, maspin expression was decreased in metastatic cancer cells in the lymph nodes, as shown in this study.
Another point of interest is that intratumor heterogeneity is partly mediated by promoter DNA methylation. We have previously reported that the allelic loss of 2q, 9p and 22q, which are associated with the advanced stage of tumors, varied in individual tumors, and that the diversity is related to morphological tumor grade (Yatabe et al., 2000) . The present study revealed that gene silencing by DNA methylation is another contributor to intratumor heterogeneity. In general, DNA methylation is stable and inheritable over cell divisions. However, selective pressure during the tumor progression may alter the pattern. Indeed, a reversible shift in methylation pattern between monolayer and spheroid culture has been reported . A recent article by Kang et al. (2003) proposed the hypothesis that metastasis is enhanced by intratumor clonal diversity superimposed on a background of poorprognosis signature property.
Infiltrating cancer cells to the stroma in small clusters are conceivable as a source of metastasis. In the current study, when the expression status is compared between the clusters and metastatic cancer cells, decreased expression is observed in half of the cases with heterogeneous expression and lymph node metastasis. This is compatible with the results in vitro that maspin functions as an invasion suppressor. However, in another comparison with a low-grade lesion and the infiltrating portion of individual tumors, the infiltrating portion expressed maspin. These findings appear to be in conflict. A similar complex issue was addressed by Graff et al. (2000) . E-cadherin is known to be heterogeneously expressed throughout all stages of malignant progression, including primary and metastatic tumors. They revealed a drift in methylation pattern of E-cadherin between monolayer and spheroid culture in vitro, suggesting a dynamic, reversible process of methylation in tumors. Based on the results, they speculated that a portion of tumor cells with decreased E-cadherin expression preferentially infiltrate to the stroma and metastasize to the lymph nodes. This is followed by an expansion of the E-cadherin-expressing portion in lymph nodes to survive in the microenvironment, because restoration of E-cadherin facilitates proliferation and cell survival through cell-to-cell interaction (Day et al., 1999) . Thus, the status in lymph nodes appears heterogeneous. Maspin may follow a similarly complex scenario. Alternatively, different processes may be involved between heterogeneous maspin expression in tumors and decreased expression in lymph nodes. Preferential expression of maspin in high histological grade tumors and in solid/infiltrating portions in individual tumors suggests the following hypothesis. Generally, maspin is expressed in accordance with the cell type. As tumors progress, the methylation maintenance system is impaired, and it alters some expression, including maspin, that results in increased heterogeneity in the individual tumors. Then, metastatic clone(s) is selected among the heterogeneous cell population according to its metastatic potential, and metastasizes to lymph nodes. This explains the findings obtained, and lack of expression in preneoplastic and in situ lesions of the peripheral type of adenocarcinoma supports the hypothesis.
Maspin is one of the target genes of the p53 pathway. It has been shown that mutated p53 lacks an ability to induce maspin (Zou et al., 2000) , and that restoration of wild-type p53 and inhibition of DNA methylation by 5-aza-doxycytidine treatment reactivate maspin expression (Oshiro et al., 2003) . In the current study, correlation between maspin expression and p53 status in lung cancers was not clear, and the expression status of maspin was not affected by p53 status in cases without promoter methylation. This implies that celltype-specific expression of maspin might function differently from induced maspin that is mediated by p53. However, two cell lines and a case of adenocarcinoma, showing a negative expression of maspin (despite no promoter hypermethylation), exhibited mutated p53. p53 may modulate the expression in some occasions. In contrast, K-ras status was associated with maspin expression in lung adenocarcinoma. It has been reported that mucinous bronchioloalveolar carcinoma (BAC) preferentially harbors a K-ras mutation (Tsuchiya et al., 1995; Marchetti et al., 1996) . Mucinous BAC is composed of neoplastic cells resembling goblet cells, which are present in the proximal airway tracts in the normal tissue. Although the mucinous BAC spreads over the peripheral lungs in a manner similar to lepidic growth, a marker of peripheral airway cells, TTF-1, is mostly negative (Goldstein and Thomas, 2001; Lau et al., 2002) , suggesting proximal airway-associated tumors of mucinous BAC. Therefore, prevalence of Kras mutations in maspin-positive adenocarcinoma might represent maspin expression in association with cell type of proximal airway cells.
It is of no doubt that the accumulation of genetic and epigenetic alterations generates a tumor. The alterations are not always the same among a certain group of tumors. Indeed, a metastatic tumor is categorized as being adjacent to the primary tumor among any other tumors with unsupervised hierarchical clustering of expression profiles. The current study used a crosssectional analysis to illustrate the difference in methylation patterns in individual tumors. The analysis gives the ability to reveal real differences independent of the background of the alterations. The analysis can be applied to various methods, including chromatin immunoprecipitation and expression profile analysis, and the results may shed light on complex phenomena in tumors in vivo.
Materials and methods

Patients
A series of 145 consecutive, non-small-cell carcinoma cases presenting between September 2000 and December 2002 at the Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan were used for the present study. In addition, five cases of atypical adenomatous hyperplasia and five cases of nonmucinous BAC were examined to determine the expression status in premalignant and in situ neoplasia. Pathological staging was determined according to the AJCC Cancer Staging Manual (Greene et al., 2002) .
Tissue microarray
In order to represent a whole tissue, four regions were selected per tumor, and tissue microarrays were constructed with an MTA-1 manual tissue arrayer (Beecher Instruments, Inc., Silver Spring, MD, USA). Briefly, selected regions of the donor paraffin block were punched with a 0.6 mm core needle, transferred and arrayed in the recipient block using the arrayer. Serial 4 mm thick sections were then placed on coated glass slides for immunohistochemical analysis.
Immunohistochemistry
Immunohistochemical examination was performed with the standard avidin-biotin-peroxidase complex method using the monoclonal antibodies against maspin (G167-70, BD Bioscience Pharmingen, San Diego, CA, USA), TTF-1 (8G7G3, DAKO, Copenhagen Denmark) and surfactant precursor protein B (19H7, Novocastra, Newcastle upon Tyne, UK). Antigens were retrieved by autoclave. Some of the tissue cores, which were missing during the procedure, or unable to be evaluated, were excluded from the analysis. Each core stained was evaluated semiquantitatively for the following criteria. A greater than moderate intensity of signal was considered as positive, and the proportion was scored as 0 ¼ negative, 1 ¼ less than 50% positive tumor cells and 2 ¼ equal to or more than 50% positive tumor cells. Averaged scores were calculated, and each case was categorized into 'mostly positive' when the averaged score was more than or equal to 1.75, 'mostly negative' when less than or equal to 0.25 and 'heterogeneous' when the score was greater than 0.25 and less than 1.75. The expression status in all cases in the heterogeneous category and 15 cases each of the mostly positive and mostly negative category was verified with staining of the corresponding whole sections.
Relative quantification by real-time RT-PCR
Total RNA was extracted from 13 cell lines, and first-strand cDNAs were synthesized using Superscript II (Invitrogen, Carlsbad, CA, USA) and random hexamer primers (Roche Applied Science, Alameda, CA, USA). Real-time quantitative PCR amplifications were performed with the Smart Cycler system (SC-100, Cepheid, Sunnyvale, CA, USA). The reactions were carried out using the QuantiTect SYBR Green PCR kit (Qiagen, Valencia, CA, USA). In each reaction, standard samples were diluted up to 1/1000 with cDNA from a lung cancer cell line, selected in preliminary experiments for each gene, and were run with unknown tumor samples. Finally, relative quantitative values from each sample were compared to their 18s rRNA values.
Mutation status of p53 and K-ras
Frozen tissue of the tumor specimens was grossly dissected to enrich for the tumor cells and to extract total RNA with the RNeasy kit (Qiagen). Using a standard RT-PCR procedure, exon 4 to exon 10 of the p53 gene was amplified, and the products directly sequenced with an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). When no mutation signals were obtained, the result was confirmed by a functional assay in yeast (Ishioka et al., 1993; Waridel et al., 1997) . When more than 10% of red colonies or significant deviation of the split assay using pWF35 and pFW34 were observed with the functional assay, RNA was re-extracted from tumor cells removed with a laser-captured microdissection system (PixCell-II, Arcturus, CA, USA), and the products of RT-PCR were sequenced. Using the same RNA as the p53 mutational analysis, the K-ras mutation was examined with direct sequencing.
Analysis of methylation status
Methylation status of the maspin promoter was examined in representative cases, including eight cases with uniformly positive expression, five cases with completely negative expression and three cases with heterogeneous expression, where the positive and negative portions were analysed separately. Genomic DNA was microdissected from frozen tissues mounted in OCT compound, to ensure that over 90% of the extract was derived from tumor cells, using a laser captured microdissection system. Then, bisulfite genomic sequencing was performed as previously described (Yatabe et al., 2001) . Briefly, converted DNA was amplified with maspin-specific primers based on the sequence obtained from Genebank (Accession NT_033907). The PCR product contained 13 CpG sites, was 153 bp downstream from an MspI site (Zou et al., 1994; Futscher et al., 2002) , and the product was located between the p53 binding site 1 and 2 (Zou et al., 2000) . The primer sequences were: forward, 5 0 -TGTTAA-GAGGTTTGAGTAGGAGAGG-3 0 and reverse, 5 0 -CCCACCTTACTTACCTAAAATCACAAT-3 0 . Amplified products were cloned (TOPO TA cloning kit, Invitrogen, Carlsbad, CA, USA), and five or more clones per case were sequenced. The averaged percentage of CpG sites was considered for methylation status of the case or tumor portion.
Statistical analysis
The w 2 test for independence and unpaired t-test compared incidences of maspin expression and frequencies of clinicopathologic variables. A P-value below 0.05 was considered statistically significant.
